JMP Securities Upgrades Halozyme Therapeutics (HALO) to Market Outperform
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $107.85 +1.63%
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
JMP Securities upgraded Halozyme Therapeutics (NASDAQ: HALO) from Market Perform to Market Outperform with a new price target of $9.00.
For more ratings news on Halozyme Therapeutics click here and for the rating history of Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $6.20 yesterday.
For more ratings news on Halozyme Therapeutics click here and for the rating history of Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $6.20 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Upgrades Portland General Electric Company (POR) to Overweight
- Rothschild Redburn Upgrades Equifax (EFX) to Buy
- Baird Upgrades Parsons Corp. (PSN) to Outperform
Create E-mail Alert Related Categories
UpgradesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
